# Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

> **NCT04968106** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut Bergonié** · enrollment: 66 (estimated)

## Conditions studied

- Resectable Sarcoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide
- **DRUG:** INCMGA00012

## Key facts

- **NCT ID:** NCT04968106
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-07
- **Primary completion:** 2025-08-06
- **Final completion:** 2028-04
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968106, "Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04968106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*